It's cardiovascular day at Primary Care Update as Kate, Mark and Henry discuss bleeding risk with diltiazem in treatment for atrial fibrillation, whether alteplase improves outcomes in patients with minor ischemic stroke, and whether to continue beta-blockers long-term after acute MI with preserved ejection fraction.

It's cardiovascular day at Primary Care Update as Kate, Mark and Henry discuss bleeding risk with diltiazem in treatment for atrial fibrillation, whether alteplase improves outcomes in patients with minor ischemic stroke, and whether to continue beta-blockers long-term after acute MI with preserved ejection fraction.

Episode 157: Bleeding risk with AF, treating minor ischemic stroke, and beta-blockers after AMI

Four healthily skeptical primary care physicians discuss the latest in primary care medicine. Join Essential Evidence Editor Mark Ebell MD, Rush University's Kate Rowland MD, MSU Professor of Medicine Gary Ferenchick MD, and POEMs co-founder Henry Barry MD, MS for this fast-paced weekly update on evidence-based primary care.

Share Episode 157: Bleeding risk with AF, treating minor ischemic stroke, and beta-blockers after AMI

Sign up to save your podcasts

Episode 157: Bleeding risk with AF, treating minor ischemic stroke, and beta-blockers after AMI

Episode 157: Bleeding risk with AF, treating minor ischemic stroke, and beta-blockers after AMI